These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 22048556)

  • 1. Psychometric testing of the decisional conflict scale: genetic testing hereditary breast and ovarian cancer.
    Katapodi MC; Munro ML; Pierce PF; Williams RA
    Nurs Res; 2011; 60(6):368-77. PubMed ID: 22048556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences between women who pursued genetic testing for hereditary breast and ovarian cancer and their at-risk relatives who did not.
    Katapodi MC; Northouse L; Pierce P; Milliron KJ; Liu G; Merajver SD
    Oncol Nurs Forum; 2011 Sep; 38(5):572-81. PubMed ID: 21875844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brief assessment of parents' attitudes toward testing minor children for hereditary breast/ovarian cancer genes: development and validation of the Pediatric BRCA1/2 Testing Attitudes Scale (P-TAS).
    Peshkin BN; DeMarco TA; Garber JE; Valdimarsdottir HB; Patenaude AF; Schneider KA; Schwartz MD; Tercyak KP
    J Pediatr Psychol; 2009 Jul; 34(6):627-38. PubMed ID: 18385162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive and emotional factors predicting decisional conflict among high-risk breast cancer survivors who receive uninformative BRCA1/2 results.
    Rini C; O'Neill SC; Valdimarsdottir H; Goldsmith RE; Jandorf L; Brown K; DeMarco TA; Peshkin BN; Schwartz MD
    Health Psychol; 2009 Sep; 28(5):569-578. PubMed ID: 19751083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychosocial barriers and facilitators for cascade genetic testing in hereditary breast and ovarian cancer: a scoping review.
    Afaya A; Kim SW; Park HS; Lim MC; Jung MS; Nam EJ; Park JS; Jeong J; Ryu JM; Kim J; Kim J; Kim M; Jin J; Han J; Kim SY; Park SY; Katapodi MC; Kim S;
    Fam Cancer; 2024 Jun; 23(2):121-132. PubMed ID: 38662264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychometric assessment of the Chinese version of the decisional conflict scale in Chinese women making decision for breast cancer surgery.
    Lam WW; Kwok M; Liao Q; Chan M; Or A; Kwong A; Suen D; Fielding R
    Health Expect; 2015 Apr; 18(2):210-20. PubMed ID: 23167846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes.
    Lerman C; Narod S; Schulman K; Hughes C; Gomez-Caminero A; Bonney G; Gold K; Trock B; Main D; Lynch J; Fulmore C; Snyder C; Lemon SJ; Conway T; Tonin P; Lenoir G; Lynch H
    JAMA; 1996 Jun; 275(24):1885-92. PubMed ID: 8648868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decision-making on preimplantation genetic diagnosis and prenatal diagnosis: a challenge for couples with hereditary breast and ovarian cancer.
    Derks-Smeets IA; Gietel-Habets JJ; Tibben A; Tjan-Heijnen VC; Meijer-Hoogeveen M; Geraedts JP; van Golde R; Gomez-Garcia E; van den Bogaart E; van Hooijdonk M; de Die-Smulders CE; van Osch LA
    Hum Reprod; 2014 May; 29(5):1103-12. PubMed ID: 24603131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Awareness and attitude regarding reproductive options of persons carrying a BRCA mutation and their partners.
    Gietel-Habets JJ; de Die-Smulders CE; Derks-Smeets IA; Tibben A; Tjan-Heijnen VC; van Golde R; Gomez-Garcia E; Kets CM; van Osch LA
    Hum Reprod; 2017 Mar; 32(3):588-597. PubMed ID: 28073972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer-related distress in unselected women with newly diagnosed breast or ovarian cancer undergoing BRCA1/2 testing without pretest genetic counseling.
    Høberg-Vetti H; Eide GE; Siglen E; Listøl W; Haavind MT; Hoogerbrugge N; Bjorvatn C
    Acta Oncol; 2019 Feb; 58(2):175-181. PubMed ID: 30334464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of two evidence-based decision aids for female BRCA1/2 mutation carriers in Germany: study protocol for a randomised controlled parallel-group trial.
    Kautz-Freimuth S; Redaèlli M; Isselhard A; Shukri A; Vodermaier A; Rhiem K; Schmutzler R; Stock S
    Trials; 2022 Feb; 23(1):157. PubMed ID: 35172875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of a Standardized Tool to Identify Women at Risk for Hereditary Breast and Ovarian.
    Hessock M; Brewer T; Hutson S; Anderson J
    Nurs Womens Health; 2021 Jun; 25(3):187-197. PubMed ID: 33933425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Communicating risk of hereditary breast and ovarian cancer with an interactive decision support tool.
    Rupert DJ; Squiers LB; Renaud JM; Whitehead NS; Osborn RJ; Furberg RD; Squire CM; Tzeng JP
    Patient Educ Couns; 2013 Aug; 92(2):188-96. PubMed ID: 23664232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA1/2 testing in hereditary breast and ovarian cancer families II: impact on relationships.
    McInerney-Leo A; Biesecker BB; Hadley DW; Kase RG; Giambarresi TR; Johnson E; Lerman C; Struewing JP
    Am J Med Genet A; 2005 Mar; 133A(2):165-9. PubMed ID: 15633195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of decision aids for female BRCA1 and BRCA2 mutation carriers: a systematic review.
    Krassuski L; Vennedey V; Stock S; Kautz-Freimuth S
    BMC Med Inform Decis Mak; 2019 Aug; 19(1):154. PubMed ID: 31370837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of the Japanese version of the Decisional Conflict Scale to investigate the value of pharmacists' information: a before and after study.
    Kawaguchi T; Azuma K; Yamaguchi T; Soeda H; Sekine Y; Koinuma M; Takeuchi H; Akashi T; Unezaki S
    BMC Med Inform Decis Mak; 2013 Apr; 13():50. PubMed ID: 23594514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
    Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
    JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Facilitating decision-making in women undergoing genetic testing for hereditary breast cancer: BRECONDA randomized controlled trial results.
    Sherman KA; Kilby CJ; Shaw LK; Winch C; Kirk J; Tucker K; Elder E
    Breast; 2017 Dec; 36():79-85. PubMed ID: 29031121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attitudes, knowledge, risk perceptions and decision-making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses.
    Bluman LG; Rimer BK; Regan Sterba K; Lancaster J; Clark S; Borstelmann N; Iglehart JD; Winer EP
    Psychooncology; 2003; 12(5):410-27. PubMed ID: 12833555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychosocial outcomes and counselee satisfaction following genetic counseling for hereditary breast and ovarian cancer: A patient-reported outcome study.
    Oberguggenberger A; Sztankay M; Morscher RJ; Sperner-Unterweger B; Weber I; Hubalek M; Kemmler G; Zschocke J; Martini C; Egle D; Dünser M; Gamper E; Meraner V
    J Psychosom Res; 2016 Oct; 89():39-45. PubMed ID: 27663109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.